Ken Griffin Lava Therapeutics Nv Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Lava Therapeutics Nv stock. As of the latest transaction made, Citadel Advisors LLC holds 12,600 shares of LVTX stock, worth $22,176. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,600
Previous 10,200
23.53%
Holding current value
$22,176
Previous $33,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LVTX
# of Institutions
26Shares Held
3.76MCall Options Held
85.8KPut Options Held
36.8K-
Redmile Group, LLC San Francisco, CA2.07MShares$3.65 Million0.24% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$1.36 Million0.68% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3368KShares$646,9440.1% of portfolio
-
Two Sigma Investments, LP New York, NY112KShares$197,8920.0% of portfolio
-
Alpha Wave Global, LP New York, NY87.4KShares$153,8180.08% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $45.4M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...